Membrane Cofactor Protein and Factor I: Mutations and Transplantation

ABSTRACT

Mutations in the genes for three complement regulators-complement factor H (CFH), membrane cofactor protein (MCP), and factor I (IF)-have now been described in patients with atypical HUS. The functional effects of these mutations have been studied in detail and have been shown to affect secretion, expression, and regulatory function. Genotype-phenotype correlations have shown that the majority of patients with CFH, MCP, and FI mutations develop end-stage renal failure. The outcome of transplantation is poor in patients known to have either a CFH or FI mutation, with approximately 80% of patients losing the graft to recurrent disease within 2 years. In contrast, patients known to have only an MCP mutation have a satisfactory transplantation outcome. This is expected because MCP is a transmembrane regulator and allografts will therefore be protected by wild-type MCP. Combined liver/kidney transplantation for patients known to have a CFH mutation has not been successful to date. There is optimism that in the future, targeted complement inhibitors will be of major therapeutic benefit in this condition.

KEYWORDS

Atypical HUS - factor H - membrane cofactor protein - factor I - complement

REFERENCES

• 1 Cole J L, Housley Jr G A, Dykman T R, MacDermott R P, Atkinson J P. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines.  Proc Natl Acad Sci USA. 1985;  82 859-863
• 2 Seya T, Atkinson J P. Functional properties of membrane cofactor protein of complement.  Biochem J. 1989;  264 581-588
• 3 Oglesby T J, Allen C J, Liszewski M K, White D J, Atkinson J P. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism.  J Exp Med. 1992;  175 1547-1551
• 4 Kojima A, Iwata K, Seya T et al.. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis.  J Immunol. 1993;  151 1519-1527
• 5 Barilla-LaBarca M L, Liszewski M K, Lambris J D, Hourcade D, Atkinson J P. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.  J Immunol. 2002;  168 6298-6304
• 6 Seya T, Turner J R, Atkinson J P. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b.  J Exp Med. 1986;  163 837-855
• 7 Liszewski M K, Farries T C, Lublin D M, Rooney I A, Atkinson J P. Control of the complement system.  Adv Immunol. 1996;  61 201-283
• 8 Post T W, Liszewski M K, Adams E M, Tedja I, Miller E A, Atkinson J P. Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype.  J Exp Med. 1991;  174 93-102
• 9 Russell S M, Sparrow R L, McKenzie I F, Purcell D F. Tissue-specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing.  Eur J Immunol. 1992;  22 1513-1518
• 10 Parker C J. Membrane Defenses Against Attack by Complement and Perforins. Berlin; Springer 1992
• 11 Morgan B P, Harris C L. Complement Regulatory Proteins. London; Academic Press 1999
• 12 Brodbeck W G, Mold C, Atkinson J P, Medof M E. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.  J Immunol. 2000;  165 3999-4006
• 13 Adams E M, Brown M C, Nunge M, Krych M, Atkinson J P. Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity.  J Immunol. 1991;  147 3005-3011
• 14 Liszewski M K, Leung M, Cui W et al.. Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46).  J Biol Chem. 2000;  275 37692-37701
• 15 Segerman A, Atkinson J P, Marttila M, Dennerquist V, Wadell G, Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor.  J Virol. 2003;  77 9183-9191
• 16 Gaggar A, Shayakhmetov D M, Lieber A. CD46 is a cellular receptor for group B adenoviruses.  Nat Med. 2003;  9 1408-1412
• 17 Warwicker P, Goodship T HJ, Donne R L et al.. Genetic studies into inherited and sporadic haemolytic uraemic syndrome.  Kidney Int. 1998;  53 836-844
• 18 Thompson R A, Winterborn M H. Hypocomplementaemia due to a genetic deficiency of beta-1H globulin.  Clin Exp Immunol. 1981;  46 110-119
• 19 Ohali M, Shalev H, Schlesinger M et al.. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H.  Pediatr Nephrol. 1998;  12 619-624
• 20 Pichette V, Querin S, Schurch W, Brun G, Lehnernetsch G, Delage J M. Familial hemolytic-uremic syndrome and homozygous factor-H deficiency.  Am J Kidney Dis. 1994;  24 936-941
• 21 Richards A, Kemp E J, Liszewski M K et al.. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.  Proc Natl Acad Sci USA. 2003;  100 12966-12971
• 22 Pirson Y, Lefebvre C, Arnout C, Van Ypersele de Strihou C. Hemolytic uremic syndrome in three adult siblings: a family study and evolution.  Clin Nephrol. 1987;  28 250-255
• 23 Noris M, Brioschi S, Caprioli J et al.. Familial haemolytic uraemic syndrome and an MCP mutation.  Lancet. 2003;  362 1542-1547
• 24 Esparza-Gordillo J, Goicoechea J E, Buil A et al.. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32.  Hum Mol Genet. 2005;  14 703-712
• 25 Vyse T J, Bates G P, Walport M J, Morley B J. The organization of the human complement factor I gene (IF): a member of the serine protease gene family.  Genomics. 1994;  24 90-98
• 26 Alper C, Abramson N, Johnston Jr R B, Jandl J H, Rosen F S. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3).  N Engl J Med. 1970;  282 350-354
• 27 Lambris J. The multifunctional role of C3, the third component of complement.  Immunol Today. 1988;  9 387-393
• 28 Vyse T, Morley B, Bartok I et al.. The molecular basis of hereditary complement factor I deficiency.  J Clin Invest. 1996;  97 925-933
• 29 Sadallah S, Gudat F, Laissue J, Spath P, Schifferli J-A. Glomerulonephritis in a patient with complement factor I deficiency.  Am J Kidney Dis. 1999;  33 1153-1157
• 30 Amadei N, Baracho G, Nudelman V, Bastos W, Florido M, Isaac L. Inherited complement factor I deficiency associated with systemic lupus erythematosus, higher susceptibility to infection and low levels of factor H.  Scand J Immunol. 2001;  53 615-621
• 31 Fremeaux-Bacchi V, Dragon-Durey M, Blouin J et al.. Complement factor I: a susceptibility gene for atypical hemolytic-uremic syndrome.  J Med Genet. 2004;  41 E84
• 32 Kavanagh D, Winney R J, Kemp E J et al.. Mutations in complement factor I (IF) predispose to the development of atypical HUS.  J Am Soc Nephrol. 2005;  16 2150-2155
• 33 Mollnes T E, Kirschfink M. Strategies of therapeutic complement inhibition.  Mol Immunol. 2006;  43 107-121
• 34 Smith G P, Smith R A. Membrane-targeted complement inhibitors.  Mol Immunol. 2001;  38 249-255
• 35 Song H, He C, Knaak C, Guthridge J M, Holers V M, Tomlinson S. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.  J Clin Invest. 2003;  111 1875-1885
• 36 Atkinson C, Song H, Lu B et al.. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.  J Clin Invest. 2005;  115 2444-2453
• 37 Donne R L, Abbs I, Barany P et al.. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor.  Am J Kidney Dis. 2002;  40 E22
• 38 Remuzzi G, Ruggenenti P, Codazzi D et al.. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.  Lancet. 2002;  359 1671-1672
• 39 Remuzzi G, Ruggenenti P, Colledan M et al.. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation.  Am J Transplant. 2005;  5 1146-1150
• 40 Cheong H I, Lee B S, Kang H G et al.. Attempted treatment of factor H deficiency by liver transplantation.  Pediatr Nephrol. 2004;  19 454-458